• Regeneron won FDA clearance for Pasatru (garetosmab-grts) to curb new HO lesions, clinician-assessed flare-ups in adults with FOP.
• Decision drew on Phase 3 OPTIMA data showing a 90%-94% drop in new lesions at 56 weeks versus placebo.
• EU filing remains under review at the European Medicines Agency.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Regeneron Pharmaceuticals Inc. published the original content used to generate this news brief on August 19, 2026, and is solely responsible for the information contained therein.